Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

<p>Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute myeloid leukemia SAN MATEO, Calif. and CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, …</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/kronos-bio-continues-to-advance-investigational-syk-inhibitors-entospletinib-and-lanraplenib-with-new-preclinical-data-at-eha2022-congress/">Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>